Value-focused investors are always on the hunt for stocks that are priced below their intrinsic value. One such stock that merits attention is Catalent Inc (CTLT, Financial). The stock, which is currently priced at 46.21, recorded a gain of 0.92% in a day and a 3-month increase of 5.28%. The stock's fair valuation is $98.64, as indicated by its GF Value.
Understanding the GF Value
The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on historical multiples (PE Ratio, PS Ratio, PB Ratio, and Price-to-Free-Cash-Flow) that the stock has traded at, GuruFocus adjustment factor based on the company's past returns and growth, and future estimates of the business performance.
However, investors need to consider a more in-depth analysis before making an investment decision. Despite its seemingly attractive valuation, certain risk factors associated with Catalent should not be ignored. These risks are primarily reflected through its low Altman Z-score of 1.3. These indicators suggest that Catalent, despite its apparent undervaluation, might be a potential value trap. This complexity underlines the importance of thorough due diligence in investment decision-making.
Decoding the Altman Z-Score
Before delving into the details, let's understand what the Altman Z-score entails. Invented by New York University Professor Edward I. Altman in 1968, the Z-Score is a financial model that predicts the probability of a company entering bankruptcy within a two-year time frame. The Altman Z-Score combines five different financial ratios, each weighted to create a final score. A score below 1.8 suggests a high likelihood of financial distress, while a score above 3 indicates a low risk.
Company Overview: Catalent Inc
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Unpacking Catalent's Low Altman Z-Score
A dissection of Catalent's Altman Z-score reveals Catalent's financial health may be weak, suggesting possible financial distress. The Retained Earnings to Total Assets ratio provides insights into a company's capability to reinvest its profits or manage debt. Evaluating Catalent's historical data, 2021: 0.00; 2022: 0.05; 2023: 0, we observe a recent decline following an initial increase in this ratio. This downward movement indicates Catalent's diminishing ability to reinvest in its business or effectively manage its debt. Consequently, it exerts a negative impact on its Z-Score.
The EBIT to Total Assets ratio serves as a crucial barometer of a company's operational effectiveness, correlating earnings before interest and taxes (EBIT) to total assets. An analysis of Catalent's EBIT to Total Assets ratio from historical data (2021: 0.09; 2022: 0.07; 2023: -0.01) indicates a descending trend. This reduction suggests that Catalent might not be utilizing its assets to their full potential to generate operational profits, which could be negatively affecting the company's overall Z-score.
Operational Efficiency and Asset Turnover
When it comes to operational efficiency, a vital indicator for Catalent is its asset turnover. The data: 2021: 0.48; 2022: 0.48; 2023: 0.40 from the past three years suggests a decreasing trend in this ratio. The asset turnover ratio reflects how effectively a company is using its assets to generate sales. Therefore, a drop in this ratio can signify reduced operational efficiency, potentially due to underutilization of assets or decreased market demand for the company's products or services. This shift in Catalent's asset turnover underlines the need for the company to reassess its operational strategies to optimize asset usage and boost sales.
Conclusion: Is Catalent a Value Trap?
Despite its attractive valuation, the low Altman Z-Score and declining ratios indicate that Catalent might be a potential value trap. These factors suggest possible financial distress and operational inefficiencies that could negatively impact future returns. Therefore, investors should consider these risks and conduct thorough due diligence before deciding to invest in Catalent.
GuruFocus Premium members can find stocks with high Altman Z-Score using the following Screener: Walter Schloss Screen .